Johnson & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies, a company that specializes in treatments for central nervous system disorders, as reported by Bloomberg.
The deal could be completed as early as mid-January 2025, although the confidential talks would not necessarily lead to an agreement.
Other potential buyers may also be interested.
Intra-Cellular’s market value has risen to $10 billion after its share price rose 40% in the 12 months to January.
The company is known for its approach to mental health and neurological disorders, with a drug for depressive disorders currently in late-stage development.
Shares rose after a recent settlement with Sandoz over Caplyta, a drug for bipolar depression.
Meanwhile, J&J’s market cap is reportedly $342 billion, after declining 12% over the same one-year period.
J&J has not commented on the potential acquisition, which would be the largest biotech transaction in more than a year, highlighting a revival in healthcare deals after a slump.
The potential acquisition comes as J&J looks to strengthen its portfolio following the spinoff of its consumer health division and the $13.1 billion acquisition of Shockwave Medical, a heart device maker.
The move is part of J&J’s strategy to sustain growth amid challenges such as the looming loss of exclusivity for its psoriasis treatment, Stelara.
In May 2024, J&J expanded its biotech footprint to include the Acquisition worth $850 million from Proteologix, which focuses on immune-mediated diseases, with additional milestone payments possible.
“Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies” was originally created and published by Pharmaceutical Technologya brand owned by GlobalData.
The information on this site has been included in good faith for general information purposes only. It is not intended to amount to advice on which reliance should be placed and we make no representation, warranty or guarantee, express or implied, as to its accuracy or completeness. You must obtain professional or specialist advice before taking or refraining from any action on the basis of the content on our site.